We’re geographically diverse
CSL Seqirus is one of the world’s largest influenza vaccine manufacturers with innovative technologies and differentiated products.
)
MANUFACTURING
Manufacturing for Global Markets
One of the largest influenza vaccine companies in the world, CSL Seqirus operates state-of-the-art manufacturing facilities in three different continents and a globally integrated supply chain for the timely supply of influenza vaccine to customers around the world. We have one of the most comprehensive influenza vaccine portfolios in the industry, tailored to the needs of health care professionals and their patients.
As part of our heritage, in Australia CSL Seqirus plays a unique public health role, continuing a long legacy as the manufacturer and sole supplier of a range of products made for the Australian Government in the National Interest, including snake and spider antivenoms and Q fever vaccine.
Manufacturing and supply in numbers
We operate advanced production facilities in the US, the UK and Australia, and manufacture influenza vaccine using both egg- and cell-based technologies.
-
1
The only influenza vaccine manufacturing facility in Australia
-
150 million
6-month capacity for pandemic vaccine doses at our Holly Springs plant
-
Approx 650
Employees at the UK’s largest biotechnology site in Liverpool
CSL Seqirus first to reach large-scale manufacture of cell-based influenza vaccines
The accelerated development of CSL Seqirus’ cell-based manufacturing technology at its state-of-the-art manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase in seasonal influenza vaccine output in just three years.
Watch video
We’re constantly improving our methods and processes
Our technical development laboratories are co-located with our manufacturing facilities. They provide the scientific and technical capability to ensure CSL Seqirus products are the best defence for the world against influenza.
Learn more
AP-CRP-23-0001